Quantum-Si trims 2026 cost outlook as Proteus pre-orders open; quarterly sales hit $212,000

Quantum-Si reported third-quarter 2026 revenue of $212,000 against a net loss of $22.3 million, a gap of more than 100 times, on 5 November. The company described the period as a handover from its Platinum instrument to Proteus, its next-generation protein-sequencing platform.

Management lowered its full-year 2026 forecasts for adjusted operating expenses and cash consumption. The revision comes after the company cut roughly a fifth of its staff in August. The exact new ranges were not available for this report.

The company said its existing funds should last until the final three months of 2028, a position it had previously set out and now repeats. That leaves about a year and a half of financing headroom after the targeted Proteus launch, assuming the plan holds.

Quantum-Si has also begun taking pre-orders for Proteus and is still aiming for commercial availability in the second quarter of 2027. Pricing, order volumes and technical specifications were not disclosed in the material reviewed, so there is no way yet to gauge early demand or how the system will be positioned against rival tools.

The company's own filing was the sole source for this article, and no additional detail on the quarter was available at the time of writing.